IMUX
Immunic Inc
NASDAQ: IMUX · HEALTHCARE · BIOTECHNOLOGY
$10.03
-6.70% today
Updated 2026-04-29
Market cap
$135.94M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-6.20
Dividend yield
—
52W range
$5 – $15
Volume
2.8M
Immunic Inc (IMUX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
+4.3%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+72.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+4.8%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+7.2%
2026-02-19
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-19 | $-0.07 | +25.8% | $0.88 | $0.94 | +7.2% |
| 2025-11-13 | $-0.13 | +13.3% | $0.76 | $0.78 | +2.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.09 | $-0.07 | +25.8% | — | — |
| 2025-09-30 | $-0.15 | $-0.13 | +13.3% | — | — |
| 2025-06-30 | $-0.17 | $-0.20 | -17.6% | — | — |
| 2025-03-31 | $-0.24 | $-0.25 | -4.2% | — | — |
| 2024-12-31 | $-0.24 | $-0.25 | -6.1% | $114000.00 | — |
| 2024-09-30 | $-0.22 | $-0.24 | -9.1% | — | — |
| 2024-06-30 | $-0.23 | $-0.21 | +8.7% | — | — |
| 2024-03-31 | $-0.26 | $-0.30 | -15.4% | — | — |
| 2023-12-31 | $-0.51 | $-0.48 | +5.9% | — | — |
| 2023-09-30 | $-0.55 | $-0.51 | +7.3% | — | — |
| 2023-06-30 | $-0.52 | $-0.54 | -3.8% | — | — |
| 2023-03-31 | $-0.52 | $-0.58 | -11.5% | — | — |
Frequently asked questions
Has Immunic Inc beaten earnings estimates?
Immunic Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of +4.3% over the last 4 quarters.
How does IMUX stock react to earnings?
IMUX stock has moved an average of +4.8% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.